X4 Pharmaceuticals, Inc (XFOR)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.60
- As of
Kresmion compiles this page from XFOR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
X4 Pharmaceuticals, Inc (XFOR): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-08.
See the full XFOR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XFOR on one page. Preview it with sample data, then open it live with a free account.
Preview the XFOR dossierActive signals for XFOR
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 95% of XFOR (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 29.2%, EPS $-0.13 vs $-0.1836 estimate
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +2062% to XFOR (2026Q1)
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 21.6% - EPS $-0.16 vs $-0.204 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 21.6% - EPS $-3.47 vs $-4.4248 estimate
FREE, NO ACCOUNT
Every signal on XFOR, as it fires
You are seeing 5 of 8 signals recorded on XFOR since 2026-05-26.
The five above landed across 5 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XFOR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 98420X202 · 2026Q2 | $192K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 98420X202 · 2026Q2 | $91K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 98420X202 · 2026Q2 | $85K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XFOR
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
XFOR against its peers
XFOR's operating margin of -247.4% ranks in the 61st percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | XFOR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 35.1M USD | 13.8M USD | 62 | 16 |
| Operating margin | -247.4% | -340.4% | 61 | 13 |
| Net margin | -225.6% | -301.7% | 54 | 13 |
| Return on equity | -42.5% | -34.7% | 37 | 22 |
| 1 year | -15.0% | -20.0% | 61 | 21 |
Peers (23): ABEO, PALI, VNDA, NAUT, BBOT, BCYC, IPSC, RCKT, IKT, EVMN, ANIK, QTTB, NWBO, ACIU, SABS, ZNTL, PRLD, EYPT, KROS, LXEO, IMRX, LCTX, LRMR. Left out: VOGX (no annual filing), VCRE (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (XFOR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XFOR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XFOR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.